Data di Pubblicazione:
2013
Citazione:
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial / Raghu, G., Behr, J., Brown, K.K., Egan, J.J., Kawut, S.M., Flaherty, K.R., Martinez, F.J., Nathan, S.D., Wells, A.U., Collard, H.R., Costabel, U., Richeldi, L., De Andrade, J., Khalil, N., Morrison, L.D., Lederer, D.J., Shao, L., Li, X., Pedersen, P.S., Montgomery, A.B., et al.. - In: ANNALS OF INTERNAL MEDICINE. - ISSN 0003-4819. - STAMPA. - 158:9(2013), pp. 641-649. [10.7326/0003-4819-158-9-201305070-00003]
Abstract:
Idiopathic pulmonary fibrosis (IPF) is characterized by formation and proliferation of fibroblast foci. Endothelin-1 induces lung fibroblast proliferation and contractile activity via the endothelin A (ETA) receptor.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Female; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Phenylpropionates; Prospective Studies; Pyridazines; Treatment Outcome; Endothelin A Receptor Antagonists
Elenco autori:
Raghu, Ganesh; Behr, Juergen; Brown, Kevin K; Egan, Jim J; Kawut, Steven M; Flaherty, Kevin R; Martinez, Fernando J; Nathan, Steven D; Wells, Athol U; Collard, Harold R; Costabel, Ulrich; Richeldi, Luca; De Andrade, Joao; Khalil, Nasreen; Morrison, Lake D; Lederer, David J; Shao, Lixin; Li, Xiaoming; Pedersen, Patty S; Montgomery, A. Bruce; Chien, Jason W; O'Riordan, Thomas G.
Link alla scheda completa:
Pubblicato in: